<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908748</url>
  </required_header>
  <id_info>
    <org_study_id>TK-254R-0201</org_study_id>
    <nct_id>NCT04908748</nct_id>
  </id_info>
  <brief_title>Esflurbiprofen Hydrogel Patch vs. Placebo in the Local Symptomatic and Short-term Treatment of Pain in Acute Strains, Sprains or Bruises of the Extremities</brief_title>
  <official_title>Randomized, Controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of an Esflurbiprofen Hydrogel Patch vs. Placebo in the Local Symptomatic and Short-term Treatment of Pain in Acute Strains, Sprains or Bruises of the Extremities Following Blunt Trauma, e.g. Sports Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teikoku Seiyaku Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinsearch GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRM Biometrics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinigen GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teikoku Seiyaku Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is:&#xD;
&#xD;
      to determine efficacy and safety of a Esflurbiprofen Hydrogel Patch compared to placebo in&#xD;
      patients with acute strains, sprains or bruises of the extremities following blunt trauma,&#xD;
      e.g. sports injuries.&#xD;
&#xD;
      to demonstrate that the Esflurbiprofen Hydrogel Patch is superior to placebo, and that the&#xD;
      patch has acceptable local tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design Randomized (1:1) (stratified by center and 2 subgroups), controlled,&#xD;
      double-blind, multi-centric study in parallel groups. Patient Population/Sample size/Study&#xD;
      Sites&#xD;
&#xD;
      The clinical trial population will consist of male or female patients, 18 - 60 years&#xD;
      suffering from acute; strains, sprains or bruises of the extremities following blunt trauma,&#xD;
      and meeting all clinical trial entry criteria.&#xD;
&#xD;
      200 patients will be enrolled (assumes a drop-out-rate of ≤10%).&#xD;
&#xD;
      The study will be performed in Germany in 3 sites&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, double-blind, multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Packages of Investigative Medicinal product will be non-distinguishable to patients, study site staff and monitors.&#xD;
Randomization data are kept strictly confidential, accessible only to authorized persons, until the time of unblinding the identity of the treatments will be concealed by the use of study drugs that are all identical in packaging, labeling, schedule of administration, appearance and odor.&#xD;
Unblinding will only occur in the case of patient emergencies and at the conclusion of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pain-on-movement (POM) compared to baseline</measure>
    <time_frame>Visit 5 (72 hours after initiating treatment) change from baseline</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of pain-on-movement (POM) compared to baseline</measure>
    <time_frame>Visit 2 (12 hours after initiating treatment) change from baseline</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pain-on-movement (POM) compared to baseline</measure>
    <time_frame>Visit 3 ( 24 hours after initiating treatment) change from baseline</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pain-on-movement (POM) compared to baseline</measure>
    <time_frame>Visit 4 (48 hours after initiating treatment) change from baseline</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pain-on-movement (POM) compared to baseline</measure>
    <time_frame>Visit 6 (96 hours after initiating treatment) change from baseline</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pain-on-movement (POM) compared to baseline</measure>
    <time_frame>Visit 7 (168 hours after initiating treatment) change from baseline</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment through questioning by the treting physician</measure>
    <time_frame>Adverse Events from Baseline for up to 7 days</time_frame>
    <description>Recording of any Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Soft Tissue Injuries</condition>
  <condition>Contusions</condition>
  <condition>Strains</condition>
  <condition>Sprains</condition>
  <condition>Bruises</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esflurbiprofen Hydrogel Patch containing 165 mg Esflurbiprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch that does not contain the active ingredient but is otherwise indistinguishable from the investigational drug Esflurbiprofen Hydrogel Patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esflurbiprofen Hydrogel Patch</intervention_name>
    <description>Esflurbiprofen is a cyclooxygenase (COX) inhibitor indicated for the treatment of osteoarthritis pain and inflammation</description>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_label>Control Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. acute sports-related soft-tissue injury/contusion (strains, sprains, bruises) of the&#xD;
             upper or lower limb&#xD;
&#xD;
          2. location of injury such that pain-on-movement (POM) is elicited on by specified&#xD;
             exercises&#xD;
&#xD;
          3. enrollment within 6 hours of the injury&#xD;
&#xD;
          4. baseline VAS score for POM of injured extremity &gt; 50 mm on a 100 mm VAS&#xD;
&#xD;
          5. size of injury, as assessed by investigator, ≥ 25 cm2 and ≤ 120 cm2&#xD;
&#xD;
          6. adult male or female patients&#xD;
&#xD;
          7. age 18 to 60 years&#xD;
&#xD;
          8. having given written informed consent&#xD;
&#xD;
          9. satisfactory health as determined by the Investigator based on medical history and&#xD;
             physical examination.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. significant concomitant injury in association with the index acute sports-related&#xD;
             soft- tissue injury/contusion; e.g. fracture, nerve injury, ligament disruption, tear&#xD;
             of muscle or cartilage, or open wound&#xD;
&#xD;
          2. excessively hairy skin at application site, cutting the hair in the injured site prior&#xD;
             to patch application will qualify for inclusion&#xD;
&#xD;
          3. current skin disorder or shaving hair at application site&#xD;
&#xD;
          4. history of excessive sweating/hyperhidrosis inclusive of application site&#xD;
&#xD;
          5. intake of NSAIDs or analgesics within 36 hours, opioids within 7 days, or&#xD;
             corticosteroids within 60 days of inclusion in the study&#xD;
&#xD;
          6. intake of long-acting NSAIDs or application of topical medication since the injury&#xD;
             (RICE allowed)&#xD;
&#xD;
          7. participation in a clinical study within 30 days before inclusion in the study or&#xD;
             concomitantly&#xD;
&#xD;
          8. drug or alcohol abuse in the opinion of the investigator&#xD;
&#xD;
          9. Pregnant and lactating women&#xD;
&#xD;
         10. Women of child-bearing potential (defined as all women physiologically capable of&#xD;
             becoming pregnant) who are not using an acceptable method of contraception defined as:&#xD;
&#xD;
               -  Surgical sterilization&#xD;
&#xD;
               -  Hormonal contraception&#xD;
&#xD;
               -  Intra Uterine Device&#xD;
&#xD;
               -  Double barrier method&#xD;
&#xD;
               -  Total abstinence throughout the study at the discretion of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Aoki</last_name>
    <role>Study Chair</role>
    <affiliation>Teikoku Sayaku Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elke Klimmeck</last_name>
    <phone>+4141711</phone>
    <phone_ext>6376</phone_ext>
    <email>e.klimmeck@clinsearch.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Giannetti, Prof. Dr.</last_name>
    <phone>+4141711</phone>
    <phone_ext>6376</phone_ext>
    <email>b.giannetti@clinsearch.de; info@clinsearch.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsche Sporthochschule Köln Institut für Kreislaufforschung und Sportmedizin</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50933</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Georg Predel, Prof. Dr.</last_name>
      <phone>+49-(0)221-4982</phone>
      <phone_ext>5270</phone_ext>
      <email>predel@dshs-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Eduard J. Ebert, Dr.</last_name>
      <phone>+49-(0)2232</phone>
      <phone_ext>48482</phone_ext>
      <email>ebert.e@web.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hans-Georg Predel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduard J. Ebert, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blunt Trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecchymosis</mesh_term>
    <mesh_term>Sprains and Strains</mesh_term>
    <mesh_term>Soft Tissue Injuries</mesh_term>
    <mesh_term>Contusions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

